|NSECT | GSECT | Quant CT/Tomo | Dual Energy | Chest Tomo | Breast Tomo | Breast Density|
|Quant. Image | Emerg. Quant. Imaging | Perf. Metrology | Clinical Trials | Emerg. Clinical
Breast Tomosynthesis - optimization and quantitation
Breast tomosynthesis is a novel 3D imaging modality that draws upon the advantages of digital mammography while addressing its main drawback of overlapping tissue.
In collaboration with Siemens Healthcare, RAI Labs is an international leader in developing this promising new technology. We were the first and only US test site for the new MAMMOMAT Novation DR Siemens digital mammography system and helped bring that product to the market. We were again the first in the US to receive their Novation TOMO (2004) and Inspiration (2009) prototypes for breast tomosynthesis.
The Siemens Novation TOMO prototype breast tomosynthesis system, located in the breast imaging clinic of Duke Hospital is shown in figure 1. The system is featured in the foreground left, while the lab members are (L-R) Lincoln Webb, Ehsan Samei PhD, and Joseph Lo PhD.
In this project, we are exploring the quantitative potential of breast tomosynthesis for the task of measuring breast density and thus cancer risk. These images are from our high risk screening cohort of subjects with atypia who are undergoing chemoprevention with Tamoxifen. We utilize tomosynthesis and MRI to provide noninvasive biomarkers for monitoring response to chemoprevention, thus providing a new care strategy consistent with the four Ps: Predictive, Preventive, Personalized, and Participatory.
Images in figure 2 show how adipose/glandular regions are seen similarly in corresponding breast tomosynthesis and MRI slices. This shows qualitatively how tomosynthesis has the potential to assess breast density.
Figure 3 shows quantitatively how our novel image processing technique has rescaled the average voxel values such that they relate linearly to the known density (%-glandular) of each lesion.